诊断多个系统缩:当前的临床指导和新兴的分子生物标志物
Meghana Goolla1,2, William P Cheshire3, Owen A Ross1,4,5
1Department of Neuroscience, Mayo Clinic, Jacksonville, FL, United States.
Frontiers in neurology
|October 16, 2023
概括
精确诊断多系统性缩 (MSA),一种罕见的神经退行性疾病,是困难的. 新兴的分子生物标志物对更早,更精确的检测和潜在的治疗有希望.
科学领域:
- 神经退行性疾病 神经退行性疾病
- 神经学 神经学
- 生物标志物发现发现
背景情况:
- 多重系统缩 (MSA) 是一种罕见的,进展性神经退行性疾病.
- 它表现为运动和自主功能障碍,经常模仿其他帕金森症疾病.
- 目前的诊断方法依赖于临床标准和排除,面临敏感性和特异性的限制.
研究的目的:
- 审查MSA的临床方面.
- 讨论目前的诊断标准及其局限性.
- 突出新兴的分子生物标志物,以改善MSA诊断.
主要方法:
- 对MSA诊断现有文献的审查.
- 对当前临床诊断标准的分析.
- 评估新型分子生物标志物研究,包括RT-QuIC试验.
主要成果:
- 由于症状与其他神经退行性疾病重叠,MSA的临床诊断具有挑战性.
- 现有的诊断方法缺乏最佳的灵敏度和特异性.
- 分子生物标志物,如α-synuclein放大试验,显示出提高诊断准确性的潜力.
结论:
- 早期和准确的MSA诊断仍然是一个重大的临床挑战.
- 新兴的分子生物标志物为改善MSA检测提供了一个有希望的途径.
- 这些生物标志物还可以指导MSA的治疗开发和治疗监测.
相关概念视频
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
11
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
11
01:26Alzheimer's Disease: Overview
503
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
503